Glaxo Group Limited

Smithkline Beecham Corporation

Fabrizio Nerozzi

Alan D Borthwick

John Liddle

Paul Graham Wyatt

Deirdre Mary Bernadette Hickey

Andrew McMurtrie Mason

Anna Katrin Szardenings

Neil Derek Miller

Steven Leslie Sollis

David George Hubert Livermore

Richard Jonathan Hatley

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

Substituted diketopiperazines as oxytocin antagonists

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a mammal in need thereof of an effective amount of a compound of the formula (I) and/or a physiologically acceptable derivative thereof, wherein the substituents have the meaning given in the description. Disclosed are also novel compounds of formula (I) and processes for their preparation.

Growing community of inventors

Stevenage, United Kingdom

Fabrizio Nerozzi